Date: 2015-12-10
Type of information: Licensing agreement
Compound: IgG2B
Company: BioInvent (Sweden) Cancer Research Technology (CRT) (UK) University of Southampton (UK)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: monoclonal antibody
Disease:
Details: * On December 10, 2015, BioInvent International announced that it has gained access to novel technology for making highly efficacious immune stimulatory antibodies to combat cancer. This initiative continues BioInvent’s long standing research collaborations with the University of Southampton. The University of Southampton, together with Cancer Research Technology (CRT), has now granted BioInvent a non-exclusive license for this specific form of antibody – IgG2B – that can work independently without needing help from other immune cells, making it more active and able to work in all tissues of the body.
The precise shape of an antibody makes a critical difference to how it can stimulate the body's immune system to fight cancer. A key research team at University of Southampton, supported by Cancer Research Technology, has been able to engineer antibodies that will be locked into the particular shape (called a locked B structure) that is most potent, making them much stronger immune stimulators than previous drugs. This achievement has recently been thoroughly described in Cancer Cell (White, A.L., Claude Chan, H.T., French, R.R. et al (2015). Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies (2015). Cancer Cell 27, 138-148).
Financial terms:
Latest news:
